Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.

Elia Rosi,Maria Thais Fastame,Francesca Prignano,Gianmarco Silvi,Antonella Di Cesare,Nicola Pimpinelli

doi:10.3390/jcm10245841

Elia Rosi, Maria Thais Fastame + Show 4 more

Open Access

https://doi.org/10.3390/jcm10245841

Copy DOI

Journal: Journal of Clinical Medicine	Publication Date: Dec 13, 2021
Citations: 3	License type: CC BY 4.0

Affiliation: University of Florence

Abstract

The Coronavirus Disease 2019 (COVID-19) pandemic, a global public health emergency, has changed dermatology practice and daily routine in just under two years. Much has been written in the literature about COVID-19-associated skin manifestations. Nevertheless, much less has been written regarding skin manifestations in patients affected by severe immune-mediated skin diseases, e.g., psoriasis and hidradenitis suppurativa, undergoing biological treatment during the COVID-19 outbreak. Thus, the aim of this article is to provide the reader with an overview of the cutaneous manifestations during the COVID-19 pandemic in this subset of patients.

Highlights

At the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)emerged in the city of Wuhan, China and spread rapidly across the world, leading the World Health Organization (WHO) to define coronavirus disease 2019 (COVID-19) as a pandemic on 11 March 2020 [1]
We collected information to answer this question: could the COVID-19 pandemic have an impact on skin manifestations of psoriatic/hidradenitis suppurativa (HS) patients undergoing biological therapy? References of relevant articles were manually searched for possible inclusion in the present review
The continuation of biologic therapy is recommended for psoriasis patients in most cases [7]

Summary

Introduction

At the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerged in the city of Wuhan, China and spread rapidly across the world, leading the World Health Organization (WHO) to define coronavirus disease 2019 (COVID-19) as a pandemic on 11 March 2020 [1]. Despite the fact that COVID-19-associated cutaneous manifestations have been progressively reported in recent months [2,3], to date, there is a paucity of literature exploring skin manifestations in psoriatic and hidradenitis suppurativa (HS) patients undergoing biological treatment during the COVID-19 outbreak. In view of these considerations, the aim of this article is to provide the reader with a comprehensive schematic overview of the cutaneous manifestations throughout the COVID-19 pandemic in this subset of patients.

Objectives

Methods

Results

Conclusion